ATG-E1 Novel Lactobacillus paracasei ATG-E1 strain and composition comprising thereof for preventing or treating respiratory disease

The present invention relates to a novel Lactobacillus paracasei ATG-E1 strain (Accession No: KCTC 14245BP) and a composition comprising the same for preventing or treating a respiratory disease, wherein the respiratory disease is induced by fine dust. The Lactobacillus paracasei ATG-E1 strain can,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	LEE YOUNG SIL, PARK JU YI, LEE DAE YOUNG, JI IL YONG, KO SEUNG HYUN, LEE YOU KYUNG, KANG, JI HEE, IM SUNG HOON, PARK GUN SEOK
Format:	Patent
Sprache:	eng ; kor
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FOODS OR FOODSTUFFS FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL PROCESSES USING MICROORGANISMS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT THEIR TREATMENT, NOT COVERED BY OTHER CLASSES VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to a novel Lactobacillus paracasei ATG-E1 strain (Accession No: KCTC 14245BP) and a composition comprising the same for preventing or treating a respiratory disease, wherein the respiratory disease is induced by fine dust. The Lactobacillus paracasei ATG-E1 strain can, by reducing the number of immune cells in bronchial alveoli and lung tissue, inhibit expression of inflammatory cytokines, such as interleukin-17A (IL-17A), tumor necrosis factor-α (TNF-α), macrophage inflammatory protein 2 (MIP2), C-X-C motif chemokine ligand 1 (CXCL-1), MIP2 (macrophage inflammatory protein-α) (MIP-1α), or interleukin-6 (IL-6), and can be used as a therapeutic agent or health functional food for various respiratory diseases including acute(chronic) bronchitis, catarrhal bronchitis, obstructive bronchitis, inflammatory bronchitis, bronchial asthma, atopic asthma, nonatopic asthma, atopic IgE-mediated asthma, allergic asthma, nonallergic asthma, chronic bronchoconstriction, acute bronchoconstriction, chronic obstructive pulmonary disease, bronchial adenoma, pulmonary tuberculosis, pulmonary emphysema, pulmonary abscess, pulmonary fibrosis, lung cancer, tracheal cancer, bronchoalveolar carcinoma, and bronchogenic carcinoma. 본 발명은 신규한 락토바실러스 파라카제이 ATG-E1 균주(Lactobacillus paracasei ATG-E1 strain, 기탁번호 KCTC 14245BP), 이를 포함하는 호흡기 질환의 예방 또는 치료용 조성물에 관한 것으로서, 상기 호흡기 질환은 미세먼지로 유도된 것을 특징으로 한다. 상기 락토바실러스 파라카제이 ATG-E1 균주는 기관지폐포, 폐조직의 면역세포수를 감소시켜 염증성 사이토카인인 IL-17A(Interleukin-17A), TNF-α(tumor necrosis factor-α), MIP2(Macrophage inflammatory protein 2), CXCL-1(C-X-C Motif Chemokine Ligand 1), MIP-1α(MIP2(Macrophage inflammatory protein-α) 또는 IL-6(Interleukin-6)의 발현을 저해하여 급만성기관지염, 카타르성기관지염, 폐쇄성기관지염, 염증성기관지염, 기관지천식, 아토피성천식, 비아토피성천식, 아토피성 IgE 매개천식, 알레르기성천식, 비알레르기성천식, 만성기관지수축, 급성기관지수축, 만성폐쇄성폐질환, 기관지선종, 폐결핵, 폐기종, 폐농양, 폐섬유화증, 폐암, 기도암, 기관지폐포암 및 기관지암 등의 다양한 호흡기 질환의 치료제 또는 건강기능식품으로 사용가능하다.